Ulipristal acetate versus placebo for fibroid treatment before surgery

New England Journal of Medicine

Volumn 366, Issue 5, 2012, Pages 409-420

  Donnez, Jacques ^a   Tatarchuk, Tetyana F ^b   Bouchard, Philippe ^d   Puscasiu, Lucian ^e   Zakharenko, Nataliya F ^c   Ivanova, Tatiana ^f   Ugocsai, Gyula ^g   Mara, Michal ^h   Jilla, Manju P ⁱ   Bestel, Elke ^j   Terrill, Paul ^k   Osterloh, Ian ^l   Loumaye, Ernest ^j  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Kiev City Clinical Hospital No 16   (Ukraine)

^c Kiev City Clinical Hospital No 9   (Ukraine)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Spitalul Clinic Judetean de Urgenta Cluj   (Romania)

^f KURSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^g Department of Obstetrics and Gynecology   (Hungary)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ Dr Jilla Hospital   (India)

^j Preglem   (Switzerland)

^k MDSL International   (United Kingdom)

^l OsterMed   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLACEBO; TARDYFERON; ULIPRISTAL;

ADULT; AMENORRHEA; ANEMIA; ARTICLE; BREAST TENDERNESS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HOT FLUSH; HUMAN; IRON THERAPY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; OVARIAN BLEEDING; PAIN; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TUMOR VOLUME; UTERUS BLEEDING; UTERUS MYOMA;

EID: 84856568733     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1103182     Document Type: Article

References (38)

1. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004;104:393-406. (Pubitemid 40458890)
2. Jacoby VL, Fujimoto VY, Giudice LC, Kuppermann M, Washington AE. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 2010;202:514-21.
3. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician 2007;75:1503-8. (Pubitemid 46790333)
4. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133-7.
5. Van Voorhis B. A 41-year-old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids. JAMA 2009;301:82-93.
6. Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update 2007;13:421-31. (Pubitemid 47303948)
7. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008;90:5 Suppl:S125-S130.
8. Somigliana E, Vercellini P, Daguati R, Pasin R, De Giorgi O, Crosignani PG. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007;13:465-76. (Pubitemid 47299852)
9. Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006;33:145-52.
10. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424-30. (Pubitemid 34661784)
11. Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K. Laparoscopic myomectomy fertility results. Ann N Y Acad Sci 2001;943:269-75. (Pubitemid 32928318)
12. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001;CD000547.
13. Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989;51:947-50. (Pubitemid 19156895)
14. Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod 1999;14:44-8. (Pubitemid 29046310)
15. Dubuisson JB, Fauconnier A, Fourchotte V, Babaki-Fard K, Coste J, Chapron C. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod 2001;16:1726-31. (Pubitemid 32761760)
16. Rossetti A, Sizzi O, Soranna L, Cucinelli F, Mancuso S, Lanzone A. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 2001;16:770-4. (Pubitemid 32293808)
17. Scialli AR, Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril 1995;64:313-20.
18. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-50. (Pubitemid 29520705)
19. Yin P, Lin Z, Reierstad S, et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010;70:1722-30.
20. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23. (Pubitemid 23155439)
21. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2011 June 6 (Epub ahead of print).
22. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010;82:41-55.
23. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36. (Pubitemid 351620347)
24. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011;95:767.e1-772.e1.
25. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307. (Pubitemid 40674206)
26. Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981-93. (Pubitemid 37532423)
27. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitaryovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582-9. (Pubitemid 47435338)
28. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188:111-23.
29. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97:734-9. (Pubitemid 20263124)
30. Melzack R. The Short-Form McGill Pain Questionnaire. Pain 1987;30:191-7. (Pubitemid 18029372)
31. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation: draft guidance (http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/ UCM135338.pdf).
32. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591-8. (Pubitemid 351589653)
33. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-90. [Erratum, Stat Med 1999;18:1293.] (Pubitemid 28185166)
34. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley, 1973:75-82.
35. Viswanathan M, Hartmann K, McKoy N, et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007;154:1-122.
36. Disorders of iron metabolism: iron deficiency and iron overload. In: Hoffman R, Benz E, Shattil S, et al. Hematology: basic principles and practice. 5th ed. New York: Churchill Livingstone, 2008:453-68.
37. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005;84:1719-26. (Pubitemid 41785670)
38. Matta WH, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989;96:200-6. (Pubitemid 19065473)